Skip to main content

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide(BIC/FTC/TAF)

  • Protocol code: MK-8591A-018
  • EudraCT code: 2019-000587-23
  • Research group: Infectious Diseases
  • Service: Infectious
  • Principal investigator:  Falcó Ferrer, Vicenç
  • Pathology: Certes malalties infeccioses i parasitàries
  • Phase: Fase III
  • Status: Recruiting volunteers